10 new companies to watch

by Alexey Bersenev on December 11, 2013 · 5 comments

in RegenMed digest

Post to Twitter Send Gmail Post to LinkedIn

I’ve decided to do an experiment and overview some new companies that I like. If you like the idea, I can do it 1-2 times per year. You can suggest new cool companies to me. In order to pick companies for this list, I relied on the following criteria:

  • Related to stem cell research, regenerative medicine, cell therapy field (therapeutic, tools, reagents, service);
  • New (0-5 years of existence) or relatively new and under-appreciated;
  • Unique approach/ platform, which excites my interest.

1. MiroMatrix Medical
The first startup, aimed to commercialize organ decellularization in tissue engineering. University of Minnesota’s spin-off.

2. jCyte
Pre-clinical stage company, commercializing cell therapy of eye diseases. Cell product derived from fetal retina. Spin-off from U California Irvine. Watch company’s presentation here.

3. VitaThreads
No web site. The first startup, commercializing biosutures. The company provides an unique approach to cell therapy delivery – via surgical threads. Worcester Polytechnic Institute’s spin-off. Read more here and here.

4. Regenerative Patch Technologies
New company, which develops embryonic stem cell-based platform (hES-derived RPE on a membrane) for macular degeneration. Watch company’s presentation here.

5. Mimetas
Microfluidics company, commercializing organ-on-chip concept. Spin-off from U of Leiden. Learn more from this video.

6. Wibi + Works
Pre-clinical stage company, commercializing mesenchymal stem cell-based therapies in diseases associated with inflammation. The unique approach allows to generate pro-inflammatory MSC1 and anti-inflammatory MSC2.

7. Editas Medicine
The first startup, aimed to commercialize genome editing by CRISPR/Cas methodology. Very impressive and unique techonology. Great leadership and foundation. MIT/ Harvard U spin-off. Three weeks ago, company has raised $43M to start.

8. RoosterBio
Very recent Lonza’s spin-off. Provides large quantities of affordable clinical-grade mesenchymal stem cells for translational studies in regenerative medicine. Unique approach and expertise. Read more here.

9. Juno Therapeutics
Very new clinical-stage company, which is commercializing two approaches in immunocellular T-cell therapy of cancer (CAR and TCR). Very powerful leadership and foundation. Company has raised $120M in the first round of investment.

10. MitoGenome Therapeutics
No web site. The first company aimed to commercialize mtDNA replacement in oocytes to treat inherited mitochondrial diseases. The person behind of IP is Shoukhrat Mitalipov.

Disclaimer: This list reflects solely my opinion and sympathy. I have no financial interest in companies, mentioned in this post. This post should not be considered as financial advice.

{ 5 comments… read them below or add one }

Roger December 12, 2013 at 5:36 am

Very nice post, Alexey. It would be great of you could do it more frequently.
The Vitathreads is very interesting. A bit on the line of the work by L’Hereux in Cytograft.


Russ December 12, 2013 at 4:47 pm

Nice post, I was surprised athersys wasn’t in your list, I believe you
Posted very positve articles in the pAst. what do you think, oversight?



Alexey Bersenev December 15, 2013 at 7:46 pm

Hi Russ,
I did not post separate articles on Athersys, but i’ve mentioned them few times in different posts. Athersys is so so old (founded in 1995) and is not meeting my criteria of “novelty” and “uniqueness” I have about equal list of “likes” and “dislikes” about them and their product.


Tanja Hakkarainen December 17, 2013 at 2:36 am

Thank you Alexey, very useful post. Regarding to Juno Therapeutics: do you know how their technology differs from U Penn’s CAR T technology (which has been licensed to Novartis)?


Aline Betancourt July 1, 2014 at 3:28 pm

Thank you Alexey. We (@Wibi+Works) are working hard to make a difference. RoosterBio is truly another company to watch! You are a constant resource for great information. Cheers, Ali


Leave a Comment

Previous post:

Next post: